0001178913-22-002402.txt : 20220621
0001178913-22-002402.hdr.sgml : 20220621
20220621060138
ACCESSION NUMBER: 0001178913-22-002402
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220316
FILED AS OF DATE: 20220621
DATE AS OF CHANGE: 20220621
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Marvin Donald
CENTRAL INDEX KEY: 0001891264
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38807
FILM NUMBER: 221025833
MAIL ADDRESS:
STREET 1: 2094 LOST CANYON RANCH CT
CITY: CASTLE ROCK
STATE: CO
ZIP: 80104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Chemomab Therapeutics Ltd.
CENTRAL INDEX KEY: 0001534248
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813676773
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: KIRYAT ATIDIM, BUILDING 7
CITY: TEL AVIV
STATE: L3
ZIP: 6158002
BUSINESS PHONE: 972-77-331-0156
MAIL ADDRESS:
STREET 1: KIRYAT ATIDIM, BUILDING 7
CITY: TEL AVIV
STATE: L3
ZIP: 6158002
FORMER COMPANY:
FORMER CONFORMED NAME: Anchiano Therapeutics Ltd.
DATE OF NAME CHANGE: 20180906
FORMER COMPANY:
FORMER CONFORMED NAME: BioCancell Ltd.
DATE OF NAME CHANGE: 20111104
4
1
ownership.xml
X0306
4
2022-03-16
0
0001534248
Chemomab Therapeutics Ltd.
CMMB
0001891264
Marvin Donald
2094 LOST CANYON RANCH CT
CASTLE ROCK
CO
80104
0
1
0
0
Executive VP, CFO & COO
American Depositary Shares
2022-03-16
4
P
0
250
3.30
A
1750
D
American Depositary Shares
2022-03-16
4
P
0
250
3.25
A
2000
D
Option to Purchase American Depositary Shares
9.77
2021-11-08
4
A
0
196875
0
A
2021-11-08
American Depositary Shares
196875
196875
D
Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
The options vest and become exercisable over a period of four (4) years, with one quarter (1/4) of the options vesting on November 8, 2022 -- the first anniversary of the grant date -- and the remainder in equal amounts over the ensuing 36 monthly periods, subject to the Reporting Person's continued service.
/s/ Matthew Rudolph, Attorney-in-Fact for Donald Marvin.
2022-06-21